News
PRTK
--
0.00%
--
Paratek (PRTK) Moves 14.5% Higher: Will This Strength Last?
Paratek (PRTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks · 4h ago
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Is Breakeven Near?
With the business potentially at an important milestone, we thought we'd take a closer look at Paratek Pharmaceuticals...
Simply Wall St. · 11h ago
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, April 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other pu...
GlobeNewswire · 04/01 21:01
Press Release: Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Dow Jones · 04/01 20:01
10-K: PARATEK PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations The following Management's...
Edgar Online - (EDG = 10Q, 10K) · 03/29 21:02
TLS, IMMP, CRMD and SYBX among after-hours movers
Gainers: [[TLS]] +21.3%. [[IMMP]] +13.1%. [[PRTK]] +6.5%. [[WIMI]] +3.8%. [[YY]] +3.4%.Losers: [[CRMD]] -8.9%. [[SYBX]] -5.3%. [[PRQR]] -4.7%. [[CD]] -4.6%. [[OLK]] -3.9%.
Seekingalpha · 03/25 21:41
Global Insomnia Drugs Market Trends , Report Explores Key Regions, Top Leading Countries, Companies, Consumption, Drivers, Forces Analysis, Revenue, Opportunity and Challenge 2021 to 2025
Mar 25, 2021 (The Expresswire) -- Global "Insomnia Drugs Market" (2021-2025) research provides key analysis on the market status of the Insomnia Drugs...
The Express Wire · 03/25 06:47
Insomnia Medication Market Analysis, Size, Share, Trends and Forecast 2020-2027 |Ameco Research
pune, India, Wed, 24 Mar 2021 07:37:08 / Comserve Inc. / -- Insomnia Medication Market 2020: This report provides a basic overview of the industry, including...
Comserve · 03/24 14:23
Insomnia Drugs Market Research Report: Industry Size, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis 2025
Mar 18, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global "Insomnia Drugs Market" report...
The Express Wire · 03/18 08:32
Neisseria Gonorrhoeae Infections Treatment Market Segmentation and Analysis by Recent Trends, consumption by Regional data, Development, Investigation, Growth by to 2026
Mar 11, 2021 (The Expresswire) -- Global “Neisseria Gonorrhoeae Infections Treatment Market” (2021-2026) to its vast repository and growth prospects of the...
The Express Wire · 03/12 03:36
Global Acute Bacterial Skin and Skin Structure Infections Treatment Market to Expand at 9.5% CAGR, Increasing Acute Bacterial Skin and Skin Structure Infections Incidence Identified as Chief Growth Driver, says Fortune Business Insights
Mar 05, 2021 (The Expresswire) -- The global “acute bacterial skin” and skin structure infections (ABSSSI) treatment market will derive growth from the...
The Express Wire · 03/05 05:18
Insomnia Therapeutics Drugs Market Includes Top Countries Figures, Business Growth, Market Size, Swot Analysis, Business Opportunity, Applications, Trends and Forecast to 2027
The Express Wire · 03/04 11:28
Paratek Pharmaceuticals (PRTK) Receives a Buy from Leerink Partners
In a report issued on February 25, Ami Fadia from Leerink Partners reiterated a Buy rating on Paratek Pharmaceuticals (PRTK), with a price target of
SmarterAnalyst · 03/04 09:06
Insomnia Treatment Market Segmentation and Analysis by Recent Trends, consumption by Regional data, Development, Investigation, Growth by to 2026
Mar 03, 2021 (The Expresswire) -- Global “Insomnia Treatment Market” (2021-2026) to its vast repository and growth prospects of the market provides the...
The Express Wire · 03/03 15:56
DJ Paratek Pharmaceuticals Initiated at Buy by Jefferies
Dow Jones · 03/02 16:27
DJ Paratek Pharmaceuticals Price Target Announced at $15.00/Share by Jefferies
Dow Jones · 03/02 16:27
--Analyst Actions: Jefferies Starts Paratek Pharmaceuticals at Buy with $15 Price Target
MT Newswires · 03/02 12:06
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, governmen...
GlobeNewswire · 03/01 21:01
Paratek Pharmace Has Returned 33.9% Since SmarTrend Recommendation (PRTK)
SmarTrend identified an Uptrend for Paratek Pharmace (NASDAQ:PRTK) on November 9th, 2020 at $5.71. In approximately 4 months, Paratek Pharmace has returned 33.92% as of today's recent price of $7.64.
Comtex SmarTrend(R) · 02/25 05:27
DJ Paratek Pharmaceuticals, Inc. CEO Evan Loh on Q4 2020 Results -- Earnings Call Transcript >PRTK
Dow Jones · 02/25 03:25
Webull provides a variety of real-time PRTK stock news. You can receive the latest news about Paratek Pharms through multiple platforms. This information may help you make smarter investment decisions.
About PRTK
Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.